LVTX LAVA Therapeutics N.V.

Biotech Analyst Ratings

Latest News

1. 17 May 2022 LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

   • LAVA-051 updated interim clinical data from Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma to be presented at 2022 ASCO Annual Meeting
   • LAVA-1207 Phase 1/2a trial in metastatic castration-resistant prostate cancer dosed the first patients and is on track to report initial data in H2 2022
   • Cash and investments of $124.2 million as of March 31, 2022
     

   UTRECHT, The Netherlands and PHILADELPHIA, May 17, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced recent corporate highlights…

   View Full Article
2. 12 May 2022 LAVA Therapeutics Announces FDA IND Clearance for LAVA-051 for the Treatment of Hematologic Malignancies

   UTRECHT, The Netherlands and PHILADELPHIA, May 12, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for LAVA-051, the Company's lead product candidate for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and acute myeloid leukemia (AML).
   

   "FDA clearance of our IND application for LAVA-051 marks the second IND for LAVA and enables us to expand patient enrollment into the U.S. for our…

   View Full Article
3. 05 May 2022 LAVA Therapeutics to Participate at the UBS Global Healthcare Conference

   UTRECHT, The Netherlands and PHILADELPHIA, May 05, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a fireside chat at the UBS Global Healthcare Conference 2022 being held in New York, NY.
   

   Presentation Details
   Format: Fireside chat
   Date: Monday, May 23, 2022
   Time: 4:15-4:45p.m. ET.

   A live webcast of the fireside chat and a replay of the fireside chat can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website…

   View Full Article
4. 27 April 2022 LAVA Therapeutics to Present Updated LAVA-051 Clinical Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

   UTRECHT, The Netherlands and PHILADELPHIA, April 27, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the Company will present updated interim data from the dose escalation phase of the ongoing Phase 1/2a clinical trial of LAVA-051 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and virtually June 3-7, 2022.
   

   The details of the poster presentation session are as follows:

   Abstract #: 2577
   Abstract Title: …

   View Full Article
5. 24 March 2022 LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

   • LAVA-051 shows encouraging initial safety and pharmacodynamic observations; on track for more dose escalation data from Phase 1/2a trial in Q2 2022
     
   • LAVA-1207 Phase 1/2a trial in mCRPC on track to report initial data in H2 2022
   • New pipeline program: LAVA-1266, a CD123-directed Gammabody™ for hematological malignancies
   • Strong balance sheet with cash and investments of $133.2 million as of December 31, 2021

   UTRECHT, The Netherlands and PHILADELPHIA, March 24, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced recent corporate highlights and financial results…

   View Full Article